Water Tower Research has initiated coverage of Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF), the London-listed biopharmaceutical company developing ketamine-based treatments for alcohol use disorder.
Analysts framed Solvonis as a late clinical-stage company trading at a microcap valuation of around $15 million, a discount to broader biotech peers.
They benchmarked the company against a group of US-listed advanced-stage CNS names valued between roughly $369 million and $5.9 billion.
The report also cited Altimmune, an alcohol use disorder company worth around $600 million, and Indivior, a commercial addiction-medicine business valued at about $5 billion.
Solvonis is advancing a phase III programme alongside a US-focused asset, preparing for phase IIb development and a proprietary discovery pipeline.
Its lead treatment, SVN-001, is a ketamine-based therapy for severe alcohol use disorder targeting the United Kingdom and selected European markets.
The second asset, SVN-002, is an esketamine oral thin film aimed at moderate-to-severe alcohol use disorder in the larger United States market.
Water Tower pointed to the scale of the addressable opportunity, estimating that around 27.9 million people have alcohol use disorder in the United States.
Of those, an estimated 11 to 12 million people with moderate-to-severe disease form the US target market for SVN-002.
A further 13 million people with severe disease across the United Kingdom and selected European markets are addressed by SVN-001.
The report put the economic burden across Solvonis' principal target markets in the hundreds of billions of dollars.
Water Tower identified the progression of SVN-002 towards a US Phase IIb trial, deeper engagement with US capital markets and the future SVN-001 readout as key potential value inflexion points.
Solvonis said the coverage formed part of its broader push to reach US investors as it advances the esketamine programme.
